<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the prevalence and the effect of coagulation <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> on the occurrence of thrombotic episodes in 120 Hungarian patients having <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) with or without <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The frequency of the <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> in Hungarian SLE patients was 13%, which is comparable with those found previously in a healthy Caucasian population </plain></SENT>
<SENT sid="2" pm="."><plain>The incidence of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> among factor V Leiden carriers has been found to be higher (odds ratio [OR] 1.7) than it is in patients without Leiden mutation (38% vs 29%) </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, the frequency of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> in the heterozygous SLE patients (OR 8.4 [confidence interval (CI) 0.8-83.9] P = 0.06) is dependent on the coexistence of other risk factors, such as <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Moreover, among heterozygous factor V SLE patients, the Leiden mutation could explain the tendency to have significantly higher prevalence of fetal losses (OR 3.9 [CI 1.2-12.0] P = 0.02) and higher prevalence of cerebrovascular lesions, cardiac <z:hpo ids='HP_0001654'>valvular abnormalities</z:hpo>, and <z:e sem="disease" ids="C0034734" disease_type="Disease or Syndrome" abbrv="">Raynaud's syndrome</z:e> than that found in individuals without <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> of those having <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0002725'>Systemic lupus erythematosus</z:hpo> patients with combined defects suffer more severely from <z:mp ids='MP_0005048'>thrombosis</z:mp> than those with a single risk factor do, suggesting that <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> is a multifactorial disorder in SLE, also </plain></SENT>
<SENT sid="6" pm="."><plain>Although, the <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e> does not seem to be a significant risk factor for <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> in SLE, these data demonstrate that Leiden mutation can be regarded as an additive thrombogenic factor providing higher predisposition to several vasoocclusive disorders in SLE </plain></SENT>
</text></document>